EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Viloxazine occupies the 5-HT2C receptor in the Macaca fascicularis brain in vivo: a [11C]CIMBI-36 positron emission tomography study

Jennie Garcia-Olivares, Brittney Yegla, Khanum Ridler, Gaia Rizzo, Zhen Fan, Amy Llopis Amenta, Anton Forsberg Moren, Christer Halldin, Vladimir Stepanov, Jennifer Koch iD, Chungping Yu, Jonathan Rubin und 2 weitere

International Journal of Neuropsychopharmacology · 10.08.2026 · 29 (8)

DOI: 10.1093/ijnp/pyag034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 23.06.2026. Verfasst von Jennie Garcia-Olivares und 13 weiteren Autor:innen. Beteiligte Einrichtung: Supernus Pharmaceuticals, Inc., Rockville, MD, United States. Hauptthemen laut MEDLINE: Brain, Receptor, Serotonin, 5-HT2C, Viloxazine, Benzylamines. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Supernus Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Efficacy of viloxazine ER (extended-release capsules; Qelbree®) for attention-deficit/hyperactivity disorder (ADHD) is attributed to its ability to increase extracellular norepinephrine and dopamine in the medial prefrontal cortex by inhibiting norepinephrine transporters (NET); however, studies also suggest potentially relevant activity at serotonin (5-HT) receptors. In this study, we evaluated the target engagement by viloxazine at 5-HT2 receptor subtypes, in species with close similarities with humans, and whether viloxazine engages 5-HT2 receptor subtypes within a clinically relevant plasma concentration range.

Methods

This study utilized positron emission tomography (PET) and was conducted to measure the relationship between viloxazine plasma concentration and the changes in binding of the agonist radioligand [11C]CIMBI-36 to 5-HT2C/5-HT2A receptors in the brain of Macaca fascicularis monkeys.

Results

Viloxazine administration reduced the binding of [11C]CIMBI-36 at 5-HT2C receptors at a concentration 10- to 20-fold lower than at 5-HT2A receptors (EC50: 4.1 vs 45.1 μM, respectively), consistent with receptor binding affinities previously measured in vitro (Ki: 0.66 vs 16.0 μM, respectively). Unbound viloxazine plasma concentrations during these PET scans were compared to human unbound concentrations at doses used to treat ADHD. Our data suggest that at clinically relevant plasma concentrations, viloxazine occupies 60%-72% of 5-HT2C receptors.

Conclusion

Our results demonstrate that at unbound viloxazine plasma concentrations comparable with those clinically relevant for the treatment of ADHD, viloxazine occupies a high proportion of 5-HT2C receptors. Occupancy of and potential functional activity at 5-HT2C receptors could therefore contribute to the therapeutic activity of viloxazine in addition to inhibition of NET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrainReceptor, Serotonin, 5-HT2CViloxazineBenzylaminesAnimalsPositron-Emission TomographyMacaca fascicularisMaleCarbon RadioisotopesFemalePhenethylamines

Stichwörter der Autor:innen

5-HT2CADHDPET[11C]CIMBI-36viloxazine

Substanzen

Receptor, Serotonin, 5-HT2CViloxazineCarbon RadioisotopesCimbi-36BenzylaminesPhenethylamines

Autor:innen und Institutionen

  • Supernus Pharmaceuticals, Inc., Rockville, MD, United States.
  • Perceptive Discovery, London, United Kingdom.
  • Karolinska Institutet, Stockholm, Sweden.
  • University of South Carolina School of Medicine, Greenville, SC, United States.
  • Duke University, Durham, NC, United States.

ORCID-Profile: Jennifer Koch

Förderung

  • Supernus Pharmaceuticals, Inc.

Zitieren

APA

Garcia-Olivares, J., Yegla, B., Ridler, K., Rizzo, G., Fan, Z., Amenta, A. L., Moren, A. F., Halldin, C., Stepanov, V., Koch, J., Yu, C., Rubin, J., Maletic, V., & Rabiner, E. A. (2026). Viloxazine occupies the 5-HT2C receptor in the Macaca fascicularis brain in vivo: a [11C]CIMBI-36 positron emission tomography study. International Journal of Neuropsychopharmacology, 29(8). https://doi.org/10.1093/ijnp/pyag034

Vancouver

Garcia-Olivares J, Yegla B, Ridler K, Rizzo G, Fan Z, Amenta AL, et al. Viloxazine occupies the 5-HT2C receptor in the Macaca fascicularis brain in vivo: a [11C]CIMBI-36 positron emission tomography study. International Journal of Neuropsychopharmacology. 2026;29(8). doi:10.1093/ijnp/pyag034

BibTeX
@article{GarciaOlivares2026,
  author = {Garcia-Olivares, Jennie and Yegla, Brittney and Ridler, Khanum and Rizzo, Gaia and Fan, Zhen and Amenta, Amy Llopis and Moren, Anton Forsberg and Halldin, Christer and Stepanov, Vladimir and Koch, Jennifer and Yu, Chungping and Rubin, Jonathan and Maletic, Vladimir and Rabiner, Eugenii A},
  title = {Viloxazine occupies the 5-HT2C receptor in the Macaca fascicularis brain in vivo: a [11C]CIMBI-36 positron emission tomography study},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2026},
  volume = {29},
  number = {8},
  doi = {10.1093/ijnp/pyag034}
}
Kostenlos starten →